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Highlights 
 Lung Cancer patients are at high risk for COVID-19 infection 
 All steps should be taken to protect patients and the healthcare workforce  
 Shortened RT overall treatment time is an important consideration during the 
COVID-19 pandemic  
 Twelve recommendations in the use of RT are proposed by an international 
panel 
 The proposed recommendations require urgent consideration during this 
pandemic  
 
 
Abstract 
 
COVID-19 has spread around the planet, sending billions of people into lockdown as 
health services struggle to cope. By April 2020, there are over a million two hundred 
thousand confirmed cases and more than sixty-five thousand deaths worldwide 
Meanwhile in Asia, where the disease began, the spread continues, in China it seems 
for now to have passed its peak. Italy, Spain, France, and the US have been the 
countries more affected in terms of deaths. The coronavirus is more dangerous to the 
elderly and those with certain pre-existing medical conditions which is precisely the 
profile of lung cancer patients. Essential cancer services should be delivered but all 
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steps should be taken to protect patients and the health workforce from infection with 
COVID-19. This presents a major challenge to radiotherapy (RT) departments 
worldwide in curbing the spread of COVID-19 while ensuring the continuity of services. 
In RT, shortening overall treatment time to reduce the number of patients present in the 
department is an important consideration. An international panel, including the majority 
of countries most affected by the COVID-19 pandemic, with expertise in the 
management of cancer in high-volume comprehensive centres from the largest 
societies of radiation oncology worldwide have come together to share their experience 
on COVID-19 preparedness in the context of lung cancer RT to deliver optimal care in 
such exceptional circumstances, based on the latest evidence. A comprehensive 
systematic review of the literature through a PubMed search was undertaken. Given 
that lung cancer is one of the most common and severe pathologies in radiation 
oncology departments, the following recommendations require particularly urgent 
consideration. The decision-making paths strongly depend on locally available 
resources, and a tailored approach should be used to attend lung cancer patients 
during this pandemic. 
 
Keywords: Lung cancer; Radiation therapy; COVID-19; Pandemic; Outbreak 
 
 
Introduction 
COVID-19 has spread around the planet, sending billions of people into lockdown as 
health services struggle to cope. By April 2020, there are over a million two hundred 
thousand confirmed cases and more than sixty-five thousand deaths worldwide [1]. 
Meanwhile in Asia, where the disease began, the spread continues, in China it seems 
for now to have passed its peak. Italy, Spain, France, and the US have been the 
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countries more affected in terms of deaths. However, limited testing and challenges in 
the attribution of the cause of death means that the number of confirmed deaths may 
not be an accurate count of the true total number of deaths from COVID-19. 
We know the coronavirus is more dangerous to the elderly and those with certain pre-
existing medical conditions. A prospective cohort study from China suggested that 
cancer patients have a higher risk of infection and poorer outcomes after COVID-19, 
compared to patients without cancer [2]. Five of the 18 cancer patients included in this 
report had lung cancer (28%). A separate retrospective study from China demonstrated 
that chronic obstructive lung disease, a condition often co-existent in lung cancer 
patients, is more common in non-surviving COVID-19 patients [3]. Lung cancer patients 
receiving immunosuppressive anticancer treatments are also likely to be at hightened 
risk of morbidity and mortality from COVID-19.   
Moreover, the data shows that over half of all those hospitalized across Spain are over 
70 years old [4]. In China, the case-fatality rate was 8% in 70 to 79 years and was 
14.8% in 80 years or older [3]. Although men and women are testing positive to 
coronavirus in similar numbers, men are more likely to be admitted into hospital and 
treated in intensive care units. Elderly men with certain pre-existing medical conditions 
is precisely the profile of lung cancer patients. The main route of viral transmission is 
respiratory droplets, and rigorous protective measures are essential to limit the extent 
of transmissibility and guarantee healthcare workers’ safety while delivering oncologic 
treatments.  
Essential cancer services should be delivered, but all steps should be taken to protect 
patients and the health workforce from infection with COVID-19. This presents a major 
challenge to radiotherapy (RT) departments worldwide in curbing the spread of COVID-
19 while ensuring the continuity of services. Individual risk from exposure to COVID-19 
varies from person to person, and all risks of COVID-19 infection should be balanced 
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against the need for tumour control and discussed on a case-by-case basis with the 
patient and their care givers. 
Everyone can still change the course of this pandemic by taking timely and concrete 
actions. Radiation oncologists are encouraged to follow protective measures as 
recommended by the World Health Organisation (e.g., frequent hand washing, social 
distancing) [5]. Additionally, many radiation oncology departments worldwide, 
especially in China, have implemented temperature screening for all users of the RT 
centre and request all patients to wear protective masks during their stay in the RT 
department even if asymptomatic [6]. In addition, keeping social distance to flatten the 
peak of the epidemic curve is a critical strategy to control the COVID-19. In RT, 
shortening overall treatment time to reduce the number of patients present in the 
treatment area at same time is an important consideration. To further reduce the time 
patients spend in the RT facilities, it is advisable to limit on-treatment visits as well, for 
instance, on demand of patients while maintaining optimal care conditions. 
 
Methods 
An international panel, including the majority of countries more affected for COVID-19 
disease, with expertise in the management of cancer at high-volume comprehensive 
centres from the largest societies of radiation oncology worldwide (European, 
American, Asian and Chinese: ESTRO, ASTRO, FARO, and CSTRO) have come 
together to share their experience on COVID-19 preparedness in the context of lung 
cancer RT to deliver optimal care to their patients in such exceptional circumstances 
based on the latest evidence. A comprehensive systematic review of the literature 
through a PubMed search was undertaken. Given that lung cancer is one of the most 
common and severe pathologies in radiation oncology departments, the following 
recommendations require particularly urgent consideration. The decision-making paths 
strongly depend on locally available resources, and a tailored approach is should be 
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used to attend lung cancer patients during this pandemic. Twelve recommendations in 
the use of RT considering shorter courses, delays, and omission of RT for lung cancer 
are proposed by the panel. 
 
Suggested recommendations (Table 1) 
Precautions for patients and health care professionals 
1. One of the most important lessons learned from RT departments in China is the 
screening of every single person who is able to get into the treatment room, 
including patients and staff. The treatment room is a confined space and is not 
easy to sterilize. Therefore, COVID-19 virus infection evaluation for all lung 
cancer patients before RT is mandatory. Recent relevant symptoms/contact 
history should be reported. COVID-19 virus should be tested before RT for 
patients with suspected infection. If positive, RT should start after the recovery 
of the infection. If negative but still suspicious, they should be treated in a single 
treatment machine at the end of the LINAC shift to limit the chances of infection 
for other patients. RT technologists and other health care personnel at 
simulation and treatment need to wear appropriate personal protective 
equipment and disinfection of the scanner/bunker must be performed 
afterwards. In the case of COVID-19 confirmed infection during treatment, the 
decision to continue or discontinue treatment should be on a case per case 
basis, keeping with the previous recommendations for protection of personnel 
and disinfection. Decision making should include patient prognosis, pre-existing 
medical conditions and the extent and symptoms of the COVID-19 infection [6]. 
For those patients with concurrent chemotherapy, it may be continued at full or 
reduced dose, or suspended, depending on the aforementioned aspects.  
Image guided radiation therapy (IGRT) 
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2. It is well known that COVID-19 pneumonia has computerized tomography (CT) 
presentations of bilateral lung opacities in 98% of chest CTs in infected patients 
and lobular and subsegmental areas of consolidation, ground glass 
consolidation, rounded morphology as the most typical radiographic findings [7, 
8]. CT finding was included as a diagnostic criteria for COVID-19 pneumonia. 
Asymptomatic infected patients pose a potential risk of spreading the virus 
without being noticed and which is a great challenge in RT clinics. Most 
recently, there have been case reports from the US and Europe that new 
ground glass opacities were caught on the images obtained by CT on rail and 
cone beam CT (CBCT) for IGRT delivery of lung stereotactic ablative 
radiotherapy (SABR). Those patients were later all tested positive for COVID-19 
even though they were totally asymptomatic. Therefore, during the COVID-19 
pandemic, we recommend careful review of simulation CT images for new 
ground glass opacities, consolidations, round morphology, and other suspicious 
image findings.   IGRT imaging (CT on rail, or CBCT) before the first fraction of 
the treatment, and subsequently, should be compared with the images of the 
simulation CT for any new image changes suspicious for COVID -19 infection. 
Patient with suspicious CT images should be sent for COVID-19 testing and be 
quarantined until the test result is known.  
 Non-small lung cancer (NSCLC) patients 
3. During this pandemic, the availability of operating rooms for surgical treatment 
may be compromised. SABR can play a critical role to offer curative treatment 
to these patients. To optimize resources, shorter schedules should be 
privileged, allowing access to more patients. Centres with experience in SABR 
treatment may deliver SABR in 1-3 fractions for stage I-II patients requiring 
thoracic RT with NSCLC. Options include 30-34Gy in one fraction for tumors < 
2 cm and ≥ 1 cm from the chest wall [9-11] and 48-54Gy in 3 fractions over 1 
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week for peripheral lesions [12]. More mild hypofractionation (45 to 60 Gy in 4 
to 8 fractions) could be considered for central and ultra-central lesions [13]. 
Lower quality evidence led to conditional recommendations on use of SABR for 
tumors >5 cm, patients with prior pneumonectomy, T3 tumors with chest wall 
invasion, synchronous multiple primary lung cancer, and as a salvage therapy 
after prior RT [14]. Consider 55-60 Gy in 20 fractions in early-stage patients not 
suitable for SABR [15].  
 
4. Deliver RT in 20 fractions (55 Gy) for stage II-III patients requiring thoracic RT 
with NSCLC. In the United Kingdom, 55 Gy in 20 fractions (2.75 Gy daily 
fractions) is the most commonly used radical NSCLC radiotherapy schedule, 
particularly for patients treated with sequential chemoradiotherapy. The phase II 
SOCCAR trial showed that schedule is associated with 50% and 46% 2-year 
survival and 2.9% and 1.7% treatment-related mortality when combined with 
concurrent and sequential chemotherapy, respectively therapy [15]. Based on 
these data, this is an acceptable approach for stage II-III NSCLC patients in the 
era of COVID-19. However, due to the lack of confirmatory level I trial evidence, 
caution needs to be exercised when using this schedule concurrent with 
chemotherapy in patients with bulky mediastinal disease. Accelerated 
hypofractionated radiation therapy with 45 Gy in 15 fractions appears to be an 
acceptable treatment option for poor performance status NSCLC patients with 
stage III inoperable tumours. A retrospective study [16] showed no differences 
between 45 Gy and standard RT (60 Gy at 2 Gy/fraction) in terms of the 
patterns of local or distant tumor control or overall survival in this subset of 
patients. 
 
5. The use of postoperative RT (PORT) for NSCLC patients is controversial. 
Multiple older studies [17] showed no survival benefit to PORT but recent data 
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suggest benefit of modern PORT for pN2 patients [18]. PORT in pN2 or 
incompletely resected stage II and III NSCLC could be reasonably delayed with 
an imaging re-evaluation before treatment at 2-3 months or treated in 20 
fractions (55 Gy) [15, 19].   
 
6. In NSCLC patients with limited metastases, there is a role for more aggressive 
treatment in all disease sites. There is a benefit to either early or late radiation 
in the setting of limited metastatic disease [20, 21]. RT could be either delayed 
while the patient is receiving systemic maintenance therapy or be an alternative 
to systemic therapy, especially when using SABR. NSCLC patients with a 
limited number of brain metastasis could be treated with stereotactic 
radiosurgery (SRS) at 1-3 fractions [22] in order to delay or potentially avoid 
whole brain radiation (WBI).  
Small-cell lung cancer (SCLC) patients 
7. Deliver SABR in 3-5 fractions for stage I-II SCLC patients requiring thoracic RT 
for peripheral lesions. Options include 60 Gy in 3 fractions, 48 Gy in 4 fractions, 
and 50 Gy in 5 fractions [23, 24]. More mild hypofractionation could be 
considered in very select patients (i.e. ultra-central lung lesions), akin to 
treatment approaches in NSCLC [13]. 
 
8. Standard of care for limited-stage SCLC patients is early or upfront concurrent 
chemoradiation with [25] thoracic RT in 15 days (45 Gy in 30 twice daily 
fractions of 1.5 Gy) [26]. During this pandemic, it may be logistically preferable 
to avoid twice-daily treatments. Studies show that perhaps doses of 40-42 Gy in 
15 daily fractions [27, 28] or 50-55 Gy in 20-25 daily fractions are comparable to 
the twice daily regimen [29, 30]. If tumor shrinkage might allow for a decrease in 
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radiation toxicities, starting RT with cycle 3 of chemotherapy may be more 
optimal for a subset of patients [31]. 
 
9. Thoracic RT for extensive-stage SCLC patients could be offered to patients with 
limited extrathoracic tumour burden after good thoracic and extrathoracic 
response to systemic treatment [32] at 30 Gy in 10 fractions [33, 34]. Slotman et 
al. [34] reported 2-year overall survival (OS) of 13% in the thoracic radiotherapy 
group versus 3% for the control group (p=0.004). 
 
10. Prophylactic cranial irradiation (PCI) has shown an improvement in OS and a 
reduction in the incidence of brain metastasis in limited-stage SCLC patients 
[35, 36] delivered at 25 Gy in 10 fractions [37].  PCI could be performed during 
radio(chemo)therapy [38] in order to avoid more days of treatment or may be 
delayed since this is a prophylactic treatment. Omission of PCI in patients with 
p-stage I SCLC may be an option due to the lower incidence of brain metastasis 
(12% at 5 years) [36, 39]. In addition, a retrospective analysis of the M.D. 
Anderson Cancer Center [40] reported no benefit of PCI in OS for patients ≥70 
years old with tumor size ≥ 5cm (2-year OS: 39% vs 41%). The role of PCI in 
extensive-stage SCLC after good response to systemic treatment is 
controversial [41]. In a Japanese trial [41], PCI did not result in longer OS 
compared with observation when patients received periodic magnetic 
resonance imaging examination during follow-up, therefore that could be an 
option. The role of reirradiation after PCI for brain metastasis is also 
controversial. A retrospective study [42] showed an OS of 58%, 50%, 21%, and 
5% after SRS, chemotherapy only , repeat whole brain irradiation (WBI; 20Gy at 
2Gy/fraction), and observation, respectively. Therefore, it could be omitted in 
patients receiving systemic treatment. SRS could be an option for patients with 
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reduced number of brain metastasis, good performance status, and controlled 
extracranial disease. 
 Palliative RT 
11. Lung cancer patients with brain metastases unsuitable for resection or SRS 
could receive dexamethasone and supportive care without WBI. The QUARTZ 
study [43] showed absence of a difference in survival, quality of life or 
dexamethasone use between patients with and without WBI. However, for 
patients with urgent indications (i.e. neurologic symptoms), WBI at 20 Gy in 5 
fractions is an option that has shown similar survival compared with longer 
courses [44]. WBI after surgery or SRS could be omitted since there is a 
modest benefit in OS in only a very selected group of patients [22, 45, 46].  
 
12. Use of single-fraction RT (8 Gy) could be an option for stage IV lung cancer 
patients with symptomatic (i.e. pain, hemoptysis, etc.) or medical emergency 
(non-brain) metastasis (i.e., superior vena cava syndrome or spinal cord 
compression) [47, 48]. Re-irradiation with the same dose to the same site could 
be considered after initial palliative RT if there is no response or an additional 
benefit from repeat treatment is expected (i.e. pain relapse after initial 
satisfactory response). Among other dose options available, we favor 20 Gy in 
5 fractions [49].  
 
Conclusions 
These recommendations on optimizing lung cancer radiation treatment worldwide 
during the COVID-19 outbreak includes the latest evidence and the combined 
experience of an international panel to help colleagues around the world for adapting 
reduced RT fractionation schemes and delay or omit RT whenever possible. This 
approach limits patient visits to protect our patients and health care professionals from 
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potential exposure to COVID-19. These tips may ease the workflow in radiation 
oncology departments during this exceptional situation. Finally, whether thoracic low 
doses and the application of radiation to treat viral pneumonia by the induction of an 
anti-inflammatory phenotype which may facilitate disease resolution [50] should be 
explored in a near future as an open window for another treatment approach.  
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Table 1. Summary of recommendations in the use of radiation therapy during the COVID-19 
pandemic. 
Context Recommendations 
Patients and 
health care 
professionals 
 Screening of every single person accessing the treatment room.  
 COVID-19 symptom assessment for all lung cancer patients before RT. 
 COVID-19 virus should be tested before RT for those patients with clinical and/or 
radiological suspected infection:  
 If positive, RT should start after the recovery of the infection.  
 If negative but still suspicious, they should be treated in a single treatment 
machine at the end of the LINAC shift, disinfected afterwards.  
 RT technologists and other healthcare personnel need to wear personal 
protective equipment, at least mask and gloves during the procedure. 
 If COVID-19 confirmed infection during treatment: decide to 
continue/discontinue treatment depending on patient prognosis, pre-existing 
medical conditions and the extent and symptoms of the COVID-19 infection. 
 Not compromising the prognosis of lung cancer patients by departing from 
guideline-recommended RT practice according ESTRO-ASTRO recommendations.  
NSCLC Early stage Offer  SABR or consider hypofractionation: 
 SABR in 1-3 fx for stage I-II patients.  
 Peripheral lesions:  
 30-34Gy in one fx for tumors < 2 cm and ≥ 1 cm 
from the chest wall.  
 48-54Gy in 3 fx for tumors ≤5 cm. 
 Central/ultra-central lesions: 45-60 Gy in 4-8 fractions. 
 55-60 Gy in 15-20 fx in patients not suitable for SABR. 
Locally advanced 
stage  
Offer hypofractionation: 
 55-60 Gy in 20 fx.  
 20-45 Gy in 5-15 fx for poor performance status patients. 
PORT Delay RT with an imaging re-evaluation before RT at 2-3 m. 
Consider hypofractionation: 
 55-60 Gy in 20 fx. 
Oligometastasis Local consolidative therapy with RT could be either delayed or 
even omitted. 
SCLC Limited-disease 
Early stage 
There is no need to modify SABR or use it in lieu of standard RT. 
When SABR is used, several options are available: 
 SABR in 3-5 fx for stage I-II patients.  
 Peripheral lesions: 60 Gy in 3 fx, 48 Gy in 4 fx, 50 Gy in 
5 fx. 
 Central/ultra-central lesions: as in NSCLC. 
Limited-disease 
Locally advanced 
stage 
It may be logistically preferable to avoid twice-daily RT. 
Consider hypofractionation: 
 40-42 Gy in 15 fx or 50-55 Gy in 20-25 fx.  
Extensive-disease Consider optional in the context of limited resources. If 
delivered, offer a short course:  
 30 Gy in 10 fx. 
PCI  Limited-stage:  
 May be delayed. 
 25 Gy in 10 fx during thoracic RT. 
 May be omitted in patients with p-stage I or ≥70 years 
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with tumor size ≥ 5cm. This option implies surveillance 
with brain MRI every 3-4 months. 
 Extensive-stage: PCI could be omitted. Follow-up with MRI.  
IGRT  Carefully review the IGRT images for suspicious image findings. 
 Patient with suspicious CT images should be sent for COVID 19 testing and be 
quarantined until the test result is known. Asymptomatic infected patients pose 
a potential risk of spreading the virus without being noticed. 
Palliative RT Brain metastases Unsuitable for resection or SRS: dexamethasone and supportive 
care without RT. 
 Patients with urgent indications: 20 Gy in 5 fx. 
 RT after surgery or SRS could be omitted. 
Other sites Offer single-fraction RT or short regimens:  
 Single-fraction of 8 Gy.  
 20 Gy in 5 fractions.  
Abbreviations: RT, radiation therapy; LINAC, linear accelerator; CT, computerized tomography; 
IGRT, image guided radiation therapy; NSCLC, non-small lung cancer; SCLC, Small lung cancer 
SABR, stereotactic ablative radiotherapy; PORT, postoperative radiation therapy; Fraction, fx; 
SRS, stereotactic radiosurgery; PCI, prophylactic cranial irradiation; MRI, magnetic resonance 
imaging. 
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